Pongpun Saokhieo, a member of the HPTN 083 study team and community working group, is a study coordinator and community educator at the Chiang Mai HIV Prevention Clinical Research Site (CRS) in Thailand. She has supported HIV research trials through multiple networks for more than 18 years.

Rondalya DeShields, MSN, RN, a member of HPTN 064 and HPTN 102 study teams, is the director of the Infectious Disease Practice, Prevention, and Clinical Research Studies at Rutgers New Jersey Medical School Department of Medicine in New Jersey. She has more than 21 years of experience in HIV care, treatment, and prevention. Rondalya’s passion is to improve the lives of underserved populations with a focus on women and LGTBQ communities.

Dr. Manya Magnus, District of Columbia clinical trial unit leader, has been site principal investor for HPTN 083 among other HPTN studies, since 2008. She is a professor and interim chair of the Department of Epidemiology at the Milken Institute School of Public Health at George Washington University in Washington, D.C. Dr. Magnus is also the co-director of the school’s M.P.H.

Dr. Hyman Scott, HTPN 083 protocol team member and co-investigator for HPTN 091 at Bridge HIV in San Francisco, is the clinical research medical director at Bridge HIV and an assistant clinical professor of Medicine at the University of California, San Francisco.